Literature DB >> 2332518

Idiopathic portal hypertension associated with cytotoxic drugs.

P Shepherd1, D J Harrison.   

Abstract

Four patients developed clinically important portal hypertension with histological features of idiopathic portal hypertension while they were receiving cytotoxic drugs for chronic myeloid leukaemia and Hodgkin's disease. Mild sclerosis of some small portal triads was the only abnormality seen at light microscopical examination in three of the four cases. In the remaining case light microscopical findings seemed to be normal. Two cases examined by electron microscopy showed perisinusoidal fibrosis; in one case this was the only abnormality detected. There is an association between idiopathic portal hypertension and the use of chemotherapeutic agents, particularly thioguanine. Adequate histological examination of liver tissue, including electron microscopic studies, is recommended for patients who develop hepatic problems while receiving cytotoxic treatment to elucidate this problem.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2332518      PMCID: PMC502331          DOI: 10.1136/jcp.43.3.206

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  18 in total

1.  Vinyl-chloride-induced liver disease. From idiopathic portal hypertension (Banti's syndrome) to Angiosarcomas.

Authors:  L B Thomas; H Popper; P D Berk; I Selikoff; H Falk
Journal:  N Engl J Med       Date:  1975-01-02       Impact factor: 91.245

2.  Idiopathic portal hypertension (perisinusoidal fibrosis) after renal transplantation.

Authors:  C Nataf; G Feldmann; D Lebrec; C Degott; J M Descamps; B Rueff; J P Benhamou
Journal:  Gut       Date:  1979-06       Impact factor: 23.059

3.  Hepatic injury from chronic hypervitaminosis a resulting in portal hypertension and ascites.

Authors:  R M Russell; J L Boyer; S A Bagheri; Z Hruban
Journal:  N Engl J Med       Date:  1974-08-29       Impact factor: 91.245

4.  Arsenic and noncirrhotic portal hypertension.

Authors:  J S Morris; M Schmid; S Newman; P J Scheuer; S Sherlock
Journal:  Gastroenterology       Date:  1974-01       Impact factor: 22.682

5.  Noncirrhotic portal fibrosis.

Authors:  S K Sama; S Bhargava; N G Nath; J R Talwar; N C Nayak; B N Tandon; K L Wig
Journal:  Am J Med       Date:  1971-08       Impact factor: 4.965

6.  Extra- and intrahepatic portal hypertension without cirrhosis (hepatoportal sclerosis).

Authors:  W P Mikkelsen; H A Edmondson; R L Peters; A G Redeker; T B Reynolds
Journal:  Ann Surg       Date:  1965-10       Impact factor: 12.969

7.  Idiopathic portal hypertension.

Authors:  J P Villeneuve; P M Huet; J G Joly; D Marleau; J Côté; A Légaré; M Lafortune; P Lavoie; A Viallet
Journal:  Am J Med       Date:  1976-10       Impact factor: 4.965

8.  Oesophageal varices associated with busulphan-thioguanine combination therapy for chronic myeloid leukaemia.

Authors:  N S Key; P M Kelly; P M Emerson; R W Chapman; N C Allan; J O McGee
Journal:  Lancet       Date:  1987-11-07       Impact factor: 79.321

9.  The pathology of noncirrhotic portal fibrosis: a review of 32 autopsy cases.

Authors:  B K Aikat; S R Bhusnurmath; P N Chhuttani; S K Mitra; D V Dutta
Journal:  Hum Pathol       Date:  1979-07       Impact factor: 3.466

10.  Portal hypertension in chronic leukaemia.

Authors:  D V Datta; S L Grover; V K Saini; B N Datta; B K Aikat; P N Chhuttani
Journal:  Br J Haematol       Date:  1975-11       Impact factor: 6.998

View more
  2 in total

Review 1.  Portal hypertension and refractory ascites associated with multicentric Castleman's disease.

Authors:  M Abarca; R J Andrade; A García-Arjona; J L Escolar; A Blanes; J M García-Hirschfeld; P González-Santos
Journal:  Dig Dis Sci       Date:  2000-04       Impact factor: 3.199

2.  "Endemic" idiopathic portal hypertension: report on 32 patients with non-cirrhotic portal fibrosis.

Authors:  C Vakili; M J Farahvash; T E Bynum
Journal:  World J Surg       Date:  1992 Jan-Feb       Impact factor: 3.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.